(NASDAQ:PLRX),
Investors can contact the law firm at no cost to learn more about recovering their losses
​LOS ANGELES, Feb. 12, 2025 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises Pliant Therapeutics, Inc. (“Pliant Therapeutics, Inc.” or “the Company”) (NASDAQ:PLRX) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. Pliant Therapeutics, Inc. investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: info@portnoylaw.com, to discuss their legal rights, or click here to join the case. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to recover their losses.
On February 7, 2025, Pliant Therapeutics voluntarily paused enrollment and dosing in its ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis. The decision followed a prespecified data review and recommendations from an independent safety panel.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm's founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA, NY and TX Bars
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com
Attorney Advertising
